Efficacy of systemic venous sampling of FGF23 to localize responsible tumors in tumor-induced rickets/osteomalacia

Efficacy of systemic venous sampling of FGF23 to localize responsible tumors in tumor-induced rickets/osteomalacia - Efficacy of systemic venous sampling of FGF23

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031742

Enrollment

Registered

2018-04-01

Start date

2018-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tumor-induced rickets/osteomalacia

Interventions

Perform octreoscan and FDG-PET/CT in patients with probable TIO. Perform systemic venous sampling of FGF23 in those with no accumulation on these imaging studies or those with tumors that need more co

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with probable TIO according to the diagnostic test for osteomalacia. Patients who are given sufficient explanation of the study and submit informed consent with a thorough understanding of the study.

Exclusion criteria

Exclusion criteria: Patients with serious kidney disease(eGFR<30 mL/min/1.73m2). Patients who are pregnant. Patients who are considered ineligible for the study by investigators' decision.

Design outcomes

Primary

Measure	Time frame
Whether a combination of systemic venous sampling of FGF23 and imaging studies, such as FDG-PET/CT and octreoscan, shows higher sensitivity and positive predictive value compared to imaging studies alone to localize responsible tumors in TIO.	—

Countries

Japan

Contacts

Public ContactNobuaki Ito

The University of Tokyo Hospital The division of Nephrology and Endocrinology

nobito-tky@umin.ac.jp0338155411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026